Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial

Watchlist | Portfolio | Dashboard

Faster, Cleaner, Better.

Point Biopharma Global Inc (PNT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]

[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]

[[ session ]] by (Cboe BZX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]

[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]

[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]

Cash Flow for [[ item.sessionDateDisplayLong ]]

Fiscal Year End Date: 12/31

(Values in U.S. thousands)

	12-2022	12-2021	12-2020	12-2019	12-2017
Cash Flows From Operating Activities
Net Income	98,293	-45,903	-13,373	N/A	N/A
Depreciation Amortization	-559	12	5	N/A	N/A
Income taxes - deferred	1,387	66	N/A	N/A	N/A
Accounts payable and accrued liabilities	4,825	-2,023	3,597	N/A	N/A
Other Working Capital	80,852	-1,176	3,304	N/A	N/A
Other Operating Activity	-1,280	4,325	-1,836	0	0
Operating Cash Flow	$183,519	$-44,699	$-8,303	$N/A	$N/A

Cash Flows From Investing Activities
PPE Investments	-12,767	-8,802	-9,797	N/A	N/A
Purchase Of Investment	-253,499	N/A	N/A	N/A	N/A
Investing Cash Flow	$-266,265	$-8,802	$-9,797	$N/A	$N/A

Cash Flows From Financing Activities
Debt Issued	N/A	N/A	3,545	N/A	N/A
Debt Repayment	N/A	-3,563	N/A	N/A	N/A
Common Stock Issued	130,359	285,333	25,426	N/A	N/A
Other Financing Activity	0	0	-325	0	0
Financing Cash Flow	$130,359	$281,770	$28,647	$N/A	$N/A

Beginning Cash Position	238,816	10,547	N/A	N/A	N/A
End Cash Position	286,428	238,816	10,547	N/A	N/A
Net Cash Flow	$47,612	$228,269	$10,547	$N/A	$N/A

Free Cash Flow
Operating Cash Flow	183,519	-44,699	-8,303	N/A	N/A
Capital Expenditure	-12,767	-8,802	-9,797	N/A	N/A
Free Cash Flow	170,752	-53,501	-18,100	0	0